Regulation of immunity and oncogenesis by the IRF transcription factor family David SavitskyTomohiko TamuraTadatsugu Taniguchi Review 05 January 2010 Pages: 489 - 510
CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages I–III melanoma patients Maria NapolitanoAlessandro OttaianoStefania Scala Original Article 25 September 2009 Pages: 511 - 517
A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells Sofía GrilleAndreína BrugniniJosé A. Chabalgoity Original Article 19 September 2009 Pages: 519 - 527
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer Barbara SeligerRobert StoehrArndt Hartmann Original Article 07 October 2009 Pages: 529 - 540
Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model Christian GinzkeySven O. Eicker Wolfgang Hamel Original Article 02 October 2009 Pages: 541 - 551
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer Rodolfo PassalacquaCarlo BuzioCaterina Caminiti Original Article 25 September 2009 Pages: 553 - 561
Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties Bhavna VermaOriana E. HawkinsJon A. Weidanz Original Article 25 September 2009 Pages: 563 - 573
FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release Johannes RolinKristin L. SandAzzam A. Maghazachi Original Article 13 October 2009 Pages: 575 - 586
Type I interferons inhibit the generation of tumor-associated macrophages Lance U’RenAmanda GuthSteven Dow Original Article 14 October 2009 Pages: 587 - 598
Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer Andrew J. RechRosemarie MickRobert H. Vonderheide Original Article 24 October 2009 Pages: 599 - 607
Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells Sylvia JanetzkiL. PriceA. Hoos Original Article Open access 06 November 2009 Pages: 609 - 618
Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program A. ManderC. GouttefangeasC. M. Britten Original Article Open access 06 January 2010 Pages: 619 - 627
Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells Zoran PopmihajlovFabio R. SantoriStanislav Vukmanovic Short Communication 18 December 2009 Pages: 629 - 633
ESCII–PIVAC meeting “Recent advances in cancer immunotherapy with an emphasis on cancer vaccines” held in Athens, 9–11 October 2008 Viktor UmanskyBarbara-ann Guinn Meeting Report 30 January 2009 Pages: 635 - 640
Erratum to: A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo Jianxin DaiBohua LiYajun Guo Erratum 07 January 2010 Pages: 641 - 642